Memantine + Donepezil: Brands, Price & Uses in Bangladesh

Established / FDA-Approved Use

Memantine + Donepezil is a fixed-dose combination indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients who are already stabilized on both individual components (donepezil 10 mg once daily and memantine at a maintenance dose).

Nature of Treatment

• Memantine + Donepezil provides symptomatic benefit (improvement or stabilization of cognition and function) — it does not stop or reverse the underlying neurodegenerative disease process.
• It combines two complementary mechanisms (an NMDA-receptor antagonist and a cholinesterase inhibitor) that are guideline-supported as combination therapy specifically in moderate-to-severe Alzheimer's disease, once a patient has already tolerated and responded to each component separately.

Not indicated for mild Alzheimer's disease, other forms of dementia (e.g., vascular dementia, Lewy body dementia) as a first-line approved use, or for any condition outside Alzheimer's dementia; such uses would be off-label and are not recommended without specialist guidance.

Adult Dosing (Moderate to Severe Alzheimer's Disease)

Starting Therapy

Memantine + Donepezil is intended for patients already stabilized on donepezil 10 mg once daily and on an effective maintenance dose of memantine (individually titrated, typically over several weeks, to minimize NMDA-related side effects). Patients are usually switched to the fixed-dose combination capsule once both individual target doses are reached and tolerated; the fixed-dose product is not generally used to initiate therapy in a treatment-naive patient.

Administration Instructions

• Take by mouth once daily in the evening, with or without food.
• Swallow the capsule whole, or carefully open it and sprinkle the entire contents on a small amount of soft food (e.g., applesauce) and consume immediately without chewing; do not divide, crush, or chew the extended-release pellets.
• If a dose is missed, do not double the next dose — take the next scheduled dose at the usual time, and consult a physician if several doses are missed.

Renal and Hepatic Adjustment

• Severe renal impairment: use the lower-strength combination (memantine 14 mg / donepezil 10 mg); not recommended in end-stage renal disease without close physician supervision.
• Hepatic impairment: use with caution, particularly in moderate-to-severe hepatic impairment, as donepezil clearance may be reduced; dose adjustment should be individualized by the treating physician.

Common Side Effects

Less Common but Serious Side Effects

• Bradycardia, syncope, or other conduction abnormalities (from the donepezil component's vagotonic effect) — see Precautions and Warnings.
• Gastrointestinal bleeding/peptic ulceration, particularly with concurrent NSAID use.
• Seizures (rare).
• Hepatic dysfunction (rare, including reports of liver injury with donepezil).
• Severe skin reactions (rare).

Patients or caregivers should seek prompt medical attention for fainting, very slow or irregular heartbeat, black/tarry stools, or seizures while taking Memantine + Donepezil.